Bisphosphonates in Perinatally Infected Children and Adolescents With Human Immunodeficiency Virus: Targeting Puberty

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2019 Oct 2

PMID 31570916

Citations 1

Authors

Robert C Kalayjian

Grace A McComsey

Affiliations

Soon will be listed here.

Citing Articles

Dietary pattern association with CD4 cells count in patients living with human immunodeficiency virus: A cross-sectional study.

Keshani P, Sarihi S, Parsaie N, Joulaei H J Public Health Res. 2023; 12(2):22799036231181200.

PMID: 37434871 PMC: 10331780. DOI: 10.1177/22799036231181200.

References

Golden N, Iglesias E, Jacobson M, Carey D, Meyer W, Schebendach J . Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2005; 90(6):3179-85. DOI: 10.1210/jc.2004-1659. View

Fisher J, Rogers M, Halasy J, Luckman S, Hughes D, Masarachia P . Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A. 1999; 96(1):133-8. PMC: 15105. DOI: 10.1073/pnas.96.1.133. View

Eastell R, Walsh J, Watts N, Siris E . Bisphosphonates for postmenopausal osteoporosis. Bone. 2011; 49(1):82-8. DOI: 10.1016/j.bone.2011.02.011. View

Loud K, Gordon C . Adolescent bone health. Arch Pediatr Adolesc Med. 2006; 160(10):1026-32. DOI: 10.1001/archpedi.160.10.1026. View

Jayasena A, Atapattu N, Lekamwasam S . Treatment of glucocorticoid-induced low bone mineral density in children: a systematic review. Int J Rheum Dis. 2015; 18(3):287-93. DOI: 10.1111/1756-185X.12560. View

Mora S, Pitukcheewanont P, Kaufman F, Nelson J, Gilsanz V . Biochemical markers of bone turnover and the volume and the density of bone in children at different stages of sexual development. J Bone Miner Res. 1999; 14(10):1664-71. DOI: 10.1359/jbmr.1999.14.10.1664. View

DiMeglio L, Wang J, Siberry G, Miller T, Geffner M, Hazra R . Bone mineral density in children and adolescents with perinatal HIV infection. AIDS. 2012; 27(2):211-20. PMC: 4157938. DOI: 10.1097/QAD.0b013e32835a9b80. View

Adeline Hennedige A, Jayasinghe J, Khajeh J, Macfarlane T . Systematic review on the incidence of bisphosphonate related osteonecrosis of the jaw in children diagnosed with osteogenesis imperfecta. J Oral Maxillofac Res. 2014; 4(4):e1. PMC: 3904727. DOI: 10.5037/jomr.2013.4401. View

Negredo E, Domingo P, Ferrer E, Estrada V, Curran A, Navarro A . Peak bone mass in young HIV-infected patients compared with healthy controls. J Acquir Immune Defic Syndr. 2013; 65(2):207-12. DOI: 10.1097/01.qai.0000435598.20104.d6. View

10.

Havens P, Stephensen C, Van Loan M, Schuster G, Woodhouse L, Flynn P . Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial. Clin Infect Dis. 2017; 66(2):220-228. PMC: 5848310. DOI: 10.1093/cid/cix753. View

11.

DiMeglio L, Peacock M . Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res. 2005; 21(1):132-40. DOI: 10.1359/JBMR.051006. View

12.

McComsey G, Kendall M, Tebas P, Swindells S, Hogg E, Alston-Smith B . Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 2007; 21(18):2473-82. DOI: 10.1097/QAD.0b013e3282ef961d. View

13.

Arpadi S, McMahon D, Abrams E, Bamji M, Purswani M, Engelson E . Effect of supplementation with cholecalciferol and calcium on 2-y bone mass accrual in HIV-infected children and adolescents: a randomized clinical trial. Am J Clin Nutr. 2012; 95(3):678-85. PMC: 3278244. DOI: 10.3945/ajcn.111.024786. View

14.

Saggese G, Baroncelli G, Bertelloni S . Puberty and bone development. Best Pract Res Clin Endocrinol Metab. 2002; 16(1):53-64. DOI: 10.1053/beem.2001.0180. View

15.

Hawker G, Ridout R, Harris V, Chase C, Fielding L, Biggar W . Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy. Arch Phys Med Rehabil. 2005; 86(2):284-8. DOI: 10.1016/j.apmr.2004.04.021. View

16.

Qaseem A, Forciea M, Denberg T, Barry M, Cooke M, Fitterman N . Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Ann Intern Med. 2017; 166(11):818-839. DOI: 10.7326/M15-1361. View